373 related articles for article (PubMed ID: 30570179)
1. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.
Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R
Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179
[TBL] [Abstract][Full Text] [Related]
2. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.
Maertens J; Selleslag D; Heinz WJ; Saulay M; Rahav G; Giladi M; Aoun M; Kovanda L; Kaufhold A; Engelhardt M; Cornely OA; Herbrecht R; Ullmann AJ
Mycoses; 2018 Nov; 61(11):868-876. PubMed ID: 30035825
[TBL] [Abstract][Full Text] [Related]
4. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.
Furfaro E; Signori A; Di Grazia C; Dominietto A; Raiola AM; Aquino S; Ghiggi C; Ghiso A; Ungaro R; Angelucci E; Viscoli C; Mikulska M
J Antimicrob Chemother; 2019 Aug; 74(8):2341-2346. PubMed ID: 31119272
[TBL] [Abstract][Full Text] [Related]
5. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
Miceli MH; Kauffman CA
Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
[TBL] [Abstract][Full Text] [Related]
6. Graded isavuconazole introduction in a patient with voriconazole allergy.
Morales MK; Harris C; Shoham S
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28851131
[TBL] [Abstract][Full Text] [Related]
7. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
8. Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study.
Hoenigl M; Prattes J; Neumeister P; Wölfler A; Krause R
Mycoses; 2018 Mar; 61(3):201-205. PubMed ID: 29112326
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis.
Herbrecht R; Kuessner D; Pooley N; Posthumus J; Escrig C
Curr Med Res Opin; 2018 Dec; 34(12):2187-2195. PubMed ID: 30022696
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.
Kohno S; Izumikawa K; Takazono T; Miyazaki T; Yoshida M; Kamei K; Ogawa K; Taniguchi S; Akashi K; Tateda K; Mukae H; Miyazaki Y; Okada F; Kanda Y; Kakeya H; Suzuki J; Kimura SI; Kishida M; Matsuda M; Niki Y
J Infect Chemother; 2023 Feb; 29(2):163-170. PubMed ID: 36307059
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial.
Cadranel J; Philippe B; Hennequin C; Bergeron A; Bergot E; Bourdin A; Cottin V; Jeanfaivre T; Godet C; Pineau M; Germaud P
Eur J Clin Microbiol Infect Dis; 2012 Nov; 31(11):3231-9. PubMed ID: 22782438
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan.
Saito T; Fujiuchi S; Tao Y; Sasaki Y; Ogawa K; Suzuki K; Tada A; Kuba M; Kato T; Kawabata M; Kurashima A; Sakatani M;
Infection; 2012 Dec; 40(6):661-7. PubMed ID: 22956473
[TBL] [Abstract][Full Text] [Related]
13. Isavuconazole for treatment of rare invasive fungal diseases.
Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Perfect JR; Oren I; Schmitt-Hoffmann AH; Giladi M; Marty FM; Rahav G
Mycoses; 2018 Aug; 61(8):518-533. PubMed ID: 29611246
[TBL] [Abstract][Full Text] [Related]
14. Isavuconazole-induced Acute Liver Failure in a Pediatric Patient With Invasive Aspergillosis.
Brivio E; Verna M; Migliorino GM; Foresti S; Zucchini N; Rovelli A
Pediatr Infect Dis J; 2019 Oct; 38(10):1035-1037. PubMed ID: 31568141
[TBL] [Abstract][Full Text] [Related]
15. Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.
Cheng MP; Orejas JL; Arbona-Haddad E; Bold TD; Solomon IH; Chen K; Pandit A; Kusztos AE; Cummins KC; Liakos A; Marty FM; Koo S; Hammond SP
Mycoses; 2020 Jan; 63(1):58-64. PubMed ID: 31587405
[TBL] [Abstract][Full Text] [Related]
16. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis.
Bongomin F; Harris C; Hayes G; Kosmidis C; Denning DW
PLoS One; 2018; 13(4):e0193732. PubMed ID: 29634721
[TBL] [Abstract][Full Text] [Related]
17. An overview of the available treatments for chronic cavitary pulmonary aspergillosis.
Sehgal IS; Dhooria S; Muthu V; Prasad KT; Agarwal R
Expert Rev Respir Med; 2020 Jul; 14(7):715-727. PubMed ID: 32249630
[TBL] [Abstract][Full Text] [Related]
18. Isavuconazole shortens the QTc interval.
Mellinghoff SC; Bassetti M; Dörfel D; Hagel S; Lehners N; Plis A; Schalk E; Vena A; Cornely OA
Mycoses; 2018 Apr; 61(4):256-260. PubMed ID: 29178247
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients.
DiPippo AJ; Rausch CR; Kontoyiannis DP
Mycoses; 2019 Jan; 62(1):81-86. PubMed ID: 30230043
[TBL] [Abstract][Full Text] [Related]
20. Real-life use of isavuconazole outside the hematological wards.
Scabini S; Lupia T; Angilletta R; De Rosa FG; Corcione S
Eur J Intern Med; 2019 Dec; 70():e10-e12. PubMed ID: 31526649
[No Abstract] [Full Text] [Related]
[Next] [New Search]
